9EH:F:F-Evolent Health Inc (EUR)

COMMON STOCK | Health Information Services |

Last Closing

USD 27.8

Change

+0.40 (+1.46)%

Market Cap

USD 3.16B

Volume

10.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides holistic total cost of care management. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
L0T:F GE HEALTHCARE TECH.INC.

+1.53 (+1.93%)

USD 35.91B
2HE:F Healthequity Inc

-1.00 (-1.42%)

USD 6.16B
4YC:F M3 INC.

+0.10 (+1.15%)

USD 5.81B
6HL0:F R1 RCM Inc

+0.10 (+0.79%)

USD 5.45B
1KJ:F 10X GENOMICS DL -00001

+2.23 (+11.83%)

USD 2.31B
6JM:F JMDC INC.

N/A

USD 1.93B
OC9:F Omnicell Inc

-1.80 (-4.50%)

USD 1.78B
19P:F Phreesia Inc

-0.20 (-0.92%)

USD 1.26B
4LL:F Teladoc Inc

+0.05 (+0.60%)

USD 1.25B
1XZ:F Ping An Healthcare and Technol..

+0.02 (+1.57%)

USD 1.21B

ETFs Containing 9EH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.95% 55% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.95% 52% F 33% F
Trailing 12 Months  
Capital Gain 15.83% 73% C 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.83% 70% C- 58% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 17.54% 91% A- 82% B
Dividend Return 17.54% 89% A- 75% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 39.64% 18% F 29% F
Risk Adjusted Return 44.26% 86% B+ 65% D
Market Capitalization 3.16B 94% A 73% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector